This site is intended for health professionals only
Sunday 16 June 2019
Share |

Topic: Latest News

June 14, 2019
Significantly more patients achieve PASI 90 and ACR 50 with the anti-interleukin-23p19 monoclonal antibody versus placebo in Phase IIB trial
The results of a Phase IIB study presented at EULAR 2019 demonstrate superior efficacy and comparable safety of tildrakizumab versus placebo in patients with psoriatic arthritis.1
 
June 13, 2019
A collaboration between hospitals and pharmacies in Cheshire and Merseyside has saved the NHS £11 million – and improved patient care
Pharmacies in Cheshire and Merseyside in the UK are being notified by their local hospital when a patient is discharged who might need help understanding changes to their medicines following their stay.
 
June 12, 2019
Cardiovascular health and physical activity levels of prostate cancer patients improve following successful interventions by community pharmacies, new research in the British Medical Journal reports
In the first study of its kind, researchers from the University of Surrey, funded by the Movember Foundation in partnership with Prostate Cancer UK, developed and tested the feasibility of community pharmacies delivering programmes to improve levels of physical activity and diet of men with prostate cancer and those who have successfully completed treatment for the disease.
 
June 11, 2019
Decision based on data from Phase III head-to-head study stopped early due to an overall survival efficacy benefit versus sunitinib, a current standard of care

Bristol-Myers Squibb has announced that the Scottish Medicines Consortium (SMC) has decided to fund the combination of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for use within NHS Scotland as a first-line treatment option for an advanced form of the most common type of kidney cancer, renal cell carcinoma (RCC), specifically in previously-untreated patients who are considered of intermediate- and poor-prognostic risk.

 

June 10, 2019
It is likely that official statistics are underestimated as there are many causes of the cancer, meaning the link to work is often not made, says GMB London
GMB Congress have passed a motion to launch an awareness campaign on the link between people working in certain industries and bladder cancer. 
 
The union has also pledged to work more closely with the HSE and ‘Fight Bladder Cancer’ charity.
 
June 10, 2019
Oral semaglutide is an investigational once-daily oral glucagon-like peptide-1 receptor agonist
Findings presented from two Phase IIIa clinical trials evaluated oral semaglutide 14mg vs Jardiance® (empagliflozin 25mg) in PIONEER 2 and oral semaglutide 14mg versus Victoza® (liraglutide 1.8mg) in PIONEER 4 over 52 weeks in adults with type 2 diabetes. 
 
Data from both trials were presented at the American Diabetes Association (ADA) 79th Scientific Sessions. 
 
June 10, 2019
An upsurge in demand for proton beam therapy was predicted as the centenary of the discovery of the proton was celebrated at a major scientific conference
Proton beam therapy, an innovative form of radiotherapy that delivers cancer treatment in a more targeted manner, has recently arrived in the UK through the Rutherford Cancer Centres and an NHS facility.
 
As the number of patients treated with this precision therapy grows, there is a debate about the benefits that this innovative treatment can bring.
 
June 6, 2019
The results support a robust set of existing data demonstrating the sustained efficacy, safety, and tolerability of continuous ibrutinib treatment in patients with CLL
Janssen has announced long-term follow-up results from two pivotal Phase III studies of Imbruvica® (ibrutinib) in patients with chronic lymphocytic leukaemia (CLL), a type of non-Hodgkin lymphoma and the most common form of leukaemia in adults.1 
 
June 6, 2019
In the Phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps with inadequate response to intranasal corticosteroids
Novartis has announced positive topline data from two Phase III, multicentre studies evaluating omalizumab (Xolair®) for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to standard-of-care (intranasal corticosteroids). 
 
Omalizumab, an injectable biologic treatment designed to target and block immunoglobulin E (IgE), met both co-primary endpoints and key secondary endpoints across both POLYP 1 and POLYP 2 Phase III trials.
June 6, 2019
The risk of pneumonia was highest among those using strong opioids, such as oxycodone or fentanyl, but the risk was also increased among those using buprenorphine, tramadol or codeine
Opioid analgesics were associated with a 30% increase in the risk of pneumonia in persons with Alzheimer’s disease, a recent study from the University of Eastern Finland shows.
 
The risk was most pronounced in the first two months of use. This is the first study to investigate the association between opioids and pneumonia in this population. The results were published in the Journal of Alzheimer’s Disease.1
 
June 6, 2019
Pancreatic Cancer Action is launching its first multi-targeted awareness initiative awareness amongst the general public, pharmacy teams and GPs to ensure as many people are aware of pancreatic cancer as possible
According to statistics from a recent survey, awareness of pancreatic cancer is low among the whole of the UK with only 8% of the population knowing a lot about the disease.
 
Every year there are around 9263 deaths from pancreatic cancer in the UK which could be prevented if awareness of the signs and symptoms was higher. The 5-year survival rate for pancreatic cancer is just 7% as it can only be cured if it is diagnosed in time for surgery. After surgery, survival rates increase to 30%.
 
May 30, 2019
QUARTZ is the first completed study of the Phase III PLATINUM clinical development program which evaluates both QMF149 and QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate)
Novartis has announced the first study results from the Phase III PLATINUM clinical development program assessing the safety and efficacy of QMF149, an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol acetate (IND - a long-acting beta agonist [LABA]) and mometasone furoate (MF - an anti-inflammatory (ICS)).
 
May 29, 2019
The PHARM-CHF trial investigated whether regularly seeing a pharmacist improves adherence to heart failure medications

Elderly patients with heart failure who see a pharmacist once a week are more likely to take their tablets and be active in daily life, according to late breaking results from the PHARM-CHF randomised controlled trial presented at Heart Failure 2019.1
 

May 23, 2019
Inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate) was superior to the standard of care (long-acting beta-agonist/inhaled corticosteroid) in terms of lung function in a Phase II study
New Phase II data for Novartis's IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol acetate, glycopyrronium bromide and mometasone furoate, delivered with the dose-confirming Breezhaler® inhalation device, has been presented at the 2019 annual international congress of the American Thoracic Society (ATS).
 
May 23, 2019
Inotersen is the world’s first and only subcutaneous RNA-targeting drug designed to reduce the production of human transthyretin protein
Akcea Therapeutics UK Ltd has announced that the National Institute for Health and Care Excellence (NICE) has published its final Highly Specialised Technologies (HST) Guidance for Tegsedi® (inotersen) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).1,2
 
May 22, 2019
Coronary angiography is an invasive procedure that provides an X-ray outline of the arteries supplying blood to the heart but there has been controversy over when to use it

Imaging provides a more precise diagnosis of a heart attack that can be used to individualise treatment. That is the main message of an expert consensus paper published in the European Heart Journal,1 and presented at EuroPCR 2019 in Paris.2
 

May 22, 2019
The worse outcome in women is largely attributable to the fact that women had about half the chance of having a shockable initial rhythm compared to men

Women who have a cardiac arrest outside the hospital setting are less likely to receive resuscitation from bystanders and more likely to die than men, according to new research published in the European Heart Journal.1
 

May 20, 2019
Over 870,000 people have taken part in clinical trials in 2018/2019 and this number marks a significant step towards the NHS Long Term Plan’s goal of reaching one million participants by 2023/24
The past 12 months has shown a positive rise in people benefiting from clinical research in England, as numbers have reached record highs with over 870,000 participants involved in clinical research studies supported by the National Institute for Health Research (NIHR) over the last year.
 
May 20, 2019
A team recently cataloged the neurological symptoms of patients who had received CAR T-cell therapy to better understand its neurotoxic side effects
The recent advent of chimeric antigen receptor (CAR) T-cell therapy has revolutionised the clinical treatment of cancer. Under the umbrella of immunotherapy, CAR T-cell treatment trains and strengthens a patient's own immune system to attack tumors. Early successes in clinical trials have led to approval of the treatment for recurrent blood cancers, including leukaemia and lymphoma.
 
May 17, 2019
Pharmacy regulators in Britain and Northern Ireland are considering making the registration assessment the same in all four UK countries.

Pharmacy regulators in Britain and Northern Ireland are considering making the registration assessment the same in all four UK countries.
 

May 15, 2019
The National Institute for health and Care Excellence (NICE) has reversed its draft decision not to recommend ocrelizumab (Ocrevus, Roche) for treating primary progressive multiple sclerosis (PPMS) in adults.

The National Institute for health and Care Excellence (NICE) has reversed its draft decision not to recommend ocrelizumab (Ocrevus, Roche) for treating primary progressive multiple sclerosis (PPMS) in adults.
 
The decision formed part of final draft guidance on the drug published last week (9 May), following an agreement between NHS England and the manufacturer that will make ocrelizumab available at a lower price.
 
The details of the commercial arrangement are confidential.
 

May 9, 2019
Familial chylomicronaemia syndrome is a debilitating disease caused by impaired function of the enzyme lipoprotein lipase, which causes high circulating levels of triglycerides in the body, leading to extreme abdominal pain and episodes of potentially fatal pancreatitis
Akcea Therapeutics and Ionis Pharmaceuticals have announced that Waylivra (volanesorsen) has received conditional marketing authorisation from the European Commission as an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.1
 
May 8, 2019
The anti-epileptic drug Epanutin will be out of stock until November in its 50mg Infatabs (phenytoin base) form due to manufacturing delays, Pfizer has announced

The anti-epileptic drug Epanutin will be out of stock until November in its 50mg Infatabs (phenytoin base) form due to manufacturing delays, Pfizer has announced.
 
The pharma company revealed that the drug, which is used to control tonic-clonic seizures and partial seizures or both, had fallen victim to delays "despite best efforts".
 

May 2, 2019
Pancreatic Cancer UK has announced that they are investing £750,000 into developing the first simple test for pancreatic cancer by 2024
Currently, pancreatic cancer is diagnosed by a CT or MRI scan and there is currently no ‘non-invasive’ detection test so a development of one would be welcomed.
 
However, whilst having a bio-marker for the disease is fantastic and something we should be investing in, this will not solve the problem of late diagnosis (which is the major cause for the extremely low survival rate in pancreatic cancer).  
 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine